Ma 2021-12-12-06, US manawa, Acoad Pharmaceutical (Nasdaq ʻO ka hoʻokolokolo IIʻo IIA, ke kapaʻiaʻo Lavond Ua heluʻia kahi mau kumuhana 189, nā wahine a pau a me nā makahiki he 5-20 mau makahiki me Rs.
ʻO Lavender kahi mea pālua,ʻo ka mea i hoʻopiliʻia, placebo-i hoʻopaʻaʻia i nā manawa he 12 Ke kīʻana i ke kīwī i ke kamaʻilioʻana a me keʻano hana hōʻailona no nā pēpē a me nā mea hoʻonaninani o kaʻoihana.
Ua hōʻike nā hopena i loaʻa he hoʻomaikaʻi nuiʻo Tromet Nā loli mai baseline ma Rsbq no ka planbo a me ka trfinete a me ka trfinete ma ka hebedoma 12 he -1.7.1.1.1 ʻO CGI-I nā helu he 3.8 vs 3.5 (P = 0.0030). Eia nō naʻe,ʻo ka hoʻololiʻana mai ka baseline ma CSB-DP-IT
ʻO nā hapa nui a me nā mea nui o ka mua o ka hanaʻana o ka lavender i hōʻikeʻia i ka hikiʻana o ka Trofinete e pili ana i ka hana I waena o lākou,ʻo nā hanana maikaʻi loa pinepineʻia:
① Diarurhea - Trust% 80.6% (97.3% o nā mea iʻoluʻolu a me ka placebo.
② ROMIVING - TROFINETIDE 26.9% (96% o ka mea e hōʻoluʻolu i ka modete) a placebo ka 9.6%;
③ʻO nā hanana hanaʻino i loaʻa ma 3.2% o nā kumuhana ma nā pūʻuluʻelua.
E hoʻomau ka kumuhana ma ka ho'āʻoʻana ma hope o ka trfinetede ma hope o ka hoʻopauʻana i ka hoʻokolokolo disping, a me Lolac-Helu E hōʻikeʻia i ka hālāwai kūkāʻana.
Post Time: Feb-17-2022